Skip to main content

Table 1 Patients’ characteristics

From: High-Mobility Group Box 1 expression predicts survival of patients after resection of adenocarcinoma of the ampulla of Vater

Variable Patients (n = 79)
Age
 Median (range) 68 (42–83)
Sex
 Male 44 (56%)
 Female 35 (44%)
Type of pancreatectomy
 PD 45 (57%)
 PpPD 31 (39%)
 SSPPD 3 (4%)
Node dissection
 D1 24 (30%)
 D2 52 (66%)
 D3 3 (4%)
Operative time (min)
 Median (range) 466 (293–856)
Blood loss (ml)
 Median (range) 850 (100–3696)
Transfusion
 Yes 19 (24%)
 No 60 (76%)
Morbidity
 Clavien-Dindo grade IIIa 35 (44%)
 Pancreatic fistula Grade B, C 20 (25%)
Tumor diameter (mm)
 Median (range) 20 (8–65)
Tumor ulceration
 Yes 22 (28%)
 No 57 (72%)
Type of adenocarcinoma
 Poorly differentiated 11 (14%)
 Moderately differentiated 22 (28%)
 Well differentiated 33 (42%)
 Papillary 12 (15%)
 Mucinous 1 (1%)
T stage (AJCC 8th)
 T1a 21 (27%)
 T1b 16 (20%)
 T2 15 (19%)
 T3a 27 (34%)
N stage (AJCC 8th)
 N0 53 (67%)
 N1 22 (28%)
 N2 4 (5%)
Overall stage (AJCC 8th)
 IA 20 (25%)
 IB 18 (23%)
 IIA 15 (19%)
 IIIA 22 (28%)
 IIIB 4 (5%)
HMGB1 staining intensity
 1 (no staining) 14 (18%)
 2 (light brown) 34 (43%)
 3 (moderate brown) 23 (29%)
 4 (brown or dark brown) 8 (10%)
HMGB1 positive cells (%)
 1 (0–25%) 32 (41%)
 2 (26–50%) 13 (16%)
 3 (51–75%) 10 (13%)
 4 (76–100%) 24 (30%)
HMGB1 expression
 High 31 (39%)
 Low 48 (61%)
Adjuvant chemotherapy
 Yes 28 (35%)
 Gem 19 (24%)
 S-1 7 (9%)
 Others 5 (6%)
 No 51 (65%)
  1. PD pancreaticoduodenectomy, PpPD pylorus-preserving pancreaticoduodenectomy, SSPPD subtotal stomach-preserving pancreaticoduodenectomy, AJCC American Joint Committee on Cancer, HMGB1 High-Mobility Group Box 1, Gem gemcitabine